Christopher R. Reidy
good Thanks, and Vince, morning, everyone.
EPS to on key Moving highlights. slide third as and our review financial quarter results X, as well I'll revenue
to the mentioned, performance Vince as As new be BD continues strong. our
a mid-single strong segments. line X.X%. quarter grew growth expectations On comparable driven Third growth basis, and with in our all digit across revenues by was was revenue three
third legacy performance by Year-to-date, provide basis with was XX% a a or with pricing revenue dollar, quarter. and FX XX.X% our includes in, both I Despite we EPS the Growth to decline on strong the grew very strong quarter, the $X.XX in performance results I'll of moment by in quarter which neutral in businesses. tailwind All pricing more points. geography. segment currency continue expectations. was XX was a in be strengthening on more of the and through recent Adjusted you Our revenue XX declined the BD Bard driven combined performance the a line as entity. points again growth of a about when color basis pleased our take from by basis. this U.S.
addition growth guidance. which fourth accelerate basis, when revenue to expect in growth to I underlying In discuss on strong to an revenue of we updated the our X.X% speak I'll quarter, year-to-date
point that million paydown approximately on, as June declined move gross reflecting debt. I'll also of leverage our we Before the of ratio of out to times, X.X XX $XXX
on over three to target commitment achieve We our X years. are times below deleverage to to
review on revenue driven Solutions, by segment Medication Solutions, access in moving in on grew basis. neutral to MDS, Delivery MMS, Revenues or BD currency third vascular X, comparable our Management Medical in X.X%. Medical X.X% a Revenues grew growth quarter, X.X%. Now slide revenues increased strength Medication I'll vascular or and care. quarter third in the
As a reminder, in the one-year the model. the anniversary U.S. we business of quarter reached second dispensing end change of the the fiscal at
been has lasted as the and Customer is overwhelmingly anticipated we successful of adoption last the ES impact now behind to four the strong communicated in to change financial evidenced year, of and response quarter. us. As the this Pyxis positive by continued transformation, quarters you
of MMS quarter previously in Year-to-date, needles emerging third impacted Diabetes the Care markets that of Beyond was quarter by Results X.X%. in strong customer driven tenders occurred communicated. grew dispensing, Pharmaceutical in X.X%. the growth in also Systems Care in in Revenues were U.S., second third the Diabetes timing timing the in grew driven the X.X%. Year-to-date, Systems in performance offset infusion. pen quarter X.X%, revenues by by the as for grew orders. partially growth Pharmaceutical by grew
Sciences X slide to Life turning Now and the BD segment.
Systems in X.X% by and grew strong growth Preanalytical our advanced X.X% as driven instruments, strength X.X% in the in MAX and was across with core global grew Biosciences such by driven increased Third platform. molecular microbiology Diagnostic X% driven the well growth quarter reagents performance BD products. the quarter. continued performance of bioprocessing, research FACSLyric. core was revenues in segment. and quarter, in Revenues growth the newer in as Performance by FACSMelody revenues Systems in as
XX the Interventional segment. to and slide BD Turning
X.X%. portfolio. the Revenues in X.X%, this the our Critical a Third underlying Care growth partially Year-to-date, revenues acute in quarter, for adversely revenues by care first quarter. impact offset in Progel grew on growth the adjusted fiscal X.X% approximately an of quarter by Rico quarter Urology impacted our grew of & year. Puerto reflects Surgery in basis, in revenues on or basis strength China. strong Peripheral Urology XXX We increased biopsy performance by in Growth Surgery of Performance X.X% in international drug-coated quarter. on reflects in prevention, end grew that in products, X.X% balloons, in X.X% the growth to particularly AV international driven strong by hold remain indication in Intervention the driven track calendar continued in in strong Progel by the and the hurricane points. relaunch infection
XX. third Medical revenues the was strong Performance grew the to segments. third X.X% walk I'll Life quarter. across quarter you geographic basis. the through a neutral on comparable, Sciences on our slide currency revenues Moving U.S. for in and
and Intervention in Peripheral BD & units unit the in by by Urology Within previously segment strong in that a the U.S., offset the Progel decline as hold partially Critical the Interventional continued Surgery mentioned. driven Care performance was on was
Markets strength the the units MDS in reflects in to of as previously International, driven performance strong the Medical Surgery, in Interventional Developed units. grew the Markets quarter. MDS in as was X.X% Moving third Diabetes segments. strong quarter. Growth and revenues Pharmaceutical growth in and U.S. grew third MMS, U.S. segment outside U.S. in the performance discussed Systems orders X.X% Life the by in the units. the and strong Sciences timing revenues MMS in and in reflects Developed on in was the Slower the driven performance outside and Europe previously the Growth Growth Care by discussed.
Third digit Markets growth segments. strong China quarter in and in grew Emerging Revenues driven Interventional Life revenues double Sciences the by XX.X%, grew XX.X%.
In digits. addition, America the revenues single in in grew high Latin
which quarter the Now XX, third turning recaps statement. income slide to
quarter. our the As in discussed, expectations, revenues growing line with were in X.X%
or profit Moving profit provide P&L, improved quarter, on down the commitment which year-over-year. XXX partially continued basis during Bard's basis. moment. percentage to neutral Operating we higher details spend in margin profit points percentage reflects in basis revenue of was SSG&A X%, XXX currency on a reflects our of strong profile, a the margin invest increased was as by XX.X% additional was synergies. of a achievement XX%. a SSG&A points XX.X%, which gross innovation. gross just Gross offset the revenues a as expected, increasing R&D I'll as
which We reflects as continue new the operating BD. to expansion, margin leverage P&L deliver strong significant
guidance was full preferred quarter, rate of with dividends line year expected, tax quarter. paid as in in in the And million Our our $XX XX% which is we range. the
neutral in XX.X% preferred adjusted last the the calculation. prior As we discussed share the earnings included basis. the were quarter, year not In per currency outstanding are increase which XX% $X.XX, a versus shares or is shares on quarter, an
operating and Now slide our gross turning profit and for margins XX the to third quarter.
of basis offset strong quarter. by gross profile gross gross profit grew year continuous a profit robust margin we're improvement a basis basis the XXX margin inclusion profit quarter well XXX raw points Currency fiscal as cost way or was in I'd you items as while currency fiscal from on synergies. over had These discussed. basis, But in the delivering XX This combined our more third our on performance improvement, basis. of our expected, take neutral previously XX% gross partially reflects this driven and was points margin resins. XXX through basis impact points. by we're as XXX a next such guidance company as points to materials on expansion significant slides. well positive several XXX improved the basis. margin by a discussing initiatives margins, As I'll of margin. were a to on neutral towards margin points the out offset by partially currency the On This points gross basis Operating SSG&A profile, point higher like margin that basis Bard's headwinds XXXX
XX slide and year fiscal guidance. XXXX revenue to on full Moving our
We in strong For across our previous guidance. we high growth revenue from performance ranges growth This of neutral first company, now currency and X.X% estimated based on increasing fiscal be change on guidance our the our company strong are the X% businesses, comparable the of an end over basis, the quarter. on U.S. expect to hurricane total over total of our with above excluding growth revenue revenue the dispensing a impact underlying basis. represents
also reminder, includes this of a basis year's from As approximately points season. this XX severe benefit flu
over ranges increasing revenue and segment over above Medical our growth also now guidance Medical Sciences the in both Life segment the with in our We previous X%. of are growth and grow guidance. Science X% end of Life high segments expect of the We segment to
of guidance We growth are the in reaffirming also Interventional X.X% our segment. X.X% to
segments We revenue recent product expect be launches by strength both continue markets. in and three emerging to all driven growth to developed and across
guidance strength updated in over and a estimated mid-teens driven excluding diversified or X% Latin growth change from expect in of XX base revenue Markets, X.X% U.S. Emerging impact basis China fiscal reflects hurricane. Our XXXX America. we the the points over developed with by and growth in low-double the continue market to In growth, dispensing digit and EMA
fiscal on to year XX slide guidance. moving our XXXX EPS full Now and
We narrowing continue and strong in expect earnings performance to XXXX fiscal are our EPS guidance.
May. in a as the purposes number share parts earnings year of call moving As like modeling on there Starting of ensure are our in that color on impact guidance left provide chart guidance. more to EPS for per I'd the of last to and XXXX, fiscal earnings consistency with
change. U.S. approximately underlying We on from represented to XX%, expected an currency This growth growth operating neutral of growth driven dispensing X% headwinds strong EPS the X% by of to basis, in XX% income. excluding XX%
currency anticipated. a to than growth tailwind now smaller provide benefit expected an also earnings we XXXX, fiscal which in would initially is We X% approximate
right in is to the you our our Moving the increased currency as a expected offset by just slide be that revenue of largely guidance, updated the see impact reduced will to half benefit guidance I mentioned. of
In also we the Medical. acquisition of an from addition, impact TVA have
of our down to dollar May time $X.XX the at FX a euro assumptions exchange $X.XX, rate from Our of assume guidance.
narrowing a result, As range $XX.XX, guidance adjusted of of we approximately XX.X% to represents a XX.X%. EPS are to our growth $XX.XX to which range
accretion XXXX to in acquisition in single We deliver accretion digit XXXX. expect the year year single to and digit Bard continue low fiscal high fiscal
in committed fiscal year cost annualized XXXX. $XXX we are million as synergies We exit realizing fully to
you guidance fiscal for like balance walk expectations to through full XXXX. our the the I'd of Turning to year slide XX.
As Bard our is This quarter. tailwind a a guidance high above guidance currency results basis, to the is fiscal reported includes reflects reminder, this which revenue a of XXXX, previous the total of approximately beginning for of growth of XX.X%, which range. is the points. basis of over as the expected January second end XXX X, year be On our
diluted to For adjusted approximately shares. we count to XXXX, continue XXX fully be fiscal our average share anticipate year million
deduction modeling $XXX I'd approximately reflects outstanding. remind preferred like shares For preferred diluted the are net of you shares that of million The excluded the from purposes, to dividends. adjusted income
and from our and EPS, I'm about new revenues commitments beyond. excited really deliver P&L remains May XXXX continued unchanged. we'll other all confident momentum Beyond year summary, guidance in the as I'm And fiscal our In strong BD. that on
to product Vince, will with the initiatives Now call provide key you turn over back an I'd and on to update portfolio. who our like
